Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

‘They hate it’: House Minority Whip describes Americans' rejection of Trump's tax bill Widow of officer who died by suicide ...

They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

About 69,000 new cases and nearly 14,000 deaths are expected this year, according to the American Cancer Society.

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.